153 related articles for article (PubMed ID: 26000292)
1. Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.
Gao L; Gao M; Yang G; Tao Y; Kong Y; Yang R; Meng X; Ai G; Wei R; Wu H; Wu X; Shi J
Biomed Res Int; 2015; 2015():459052. PubMed ID: 26000292
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
[TBL] [Abstract][Full Text] [Related]
3. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S
Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
[TBL] [Abstract][Full Text] [Related]
6. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A; Miki H; Oda A; Nakamura S; Teramachi J; Amachi R; Tenshin H; Hiasa M; Iwasa M; Harada T; Fujii S; Sogabe K; Kagawa K; Yoshida S; Endo I; Aihara K; Abe M
Oncotarget; 2016 Nov; 7(48):79064-79075. PubMed ID: 27738323
[TBL] [Abstract][Full Text] [Related]
7. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.
Gao M; Gao L; Tao Y; Hou J; Yang G; Wu X; Xu H; Tompkins VS; Han Y; Wu H; Zhan F; Shi J
Acta Biochim Biophys Sin (Shanghai); 2014 Jun; 46(6):484-91. PubMed ID: 24801128
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Dasmahapatra G; Patel H; Friedberg J; Quayle SN; Jones SS; Grant S
Mol Cancer Ther; 2014 Dec; 13(12):2886-97. PubMed ID: 25239935
[TBL] [Abstract][Full Text] [Related]
11. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
[TBL] [Abstract][Full Text] [Related]
13. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
Ramakrishnan V; Kimlinger T; Timm M; Haug J; Rajkumar SV; Kumar S
Leuk Res; 2014 Nov; 38(11):1358-66. PubMed ID: 25282334
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
[TBL] [Abstract][Full Text] [Related]
15. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.
Gao M; Chen G; Wang H; Xie B; Hu L; Kong Y; Yang G; Tao Y; Han Y; Wu X; Zhang Y; Dai B; Shi J
Oncotarget; 2016 May; 7(20):29102-15. PubMed ID: 27074555
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
Zhang L; Ma YP; Jia G; Lu YJ; Zhang L; Lu H; Chang MX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1122-6. PubMed ID: 23114131
[TBL] [Abstract][Full Text] [Related]
18. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction.
Seo SK; Lee HC; Woo SH; Jin HO; Yoo DH; Lee SJ; An S; Choe TB; Park MJ; Hong SI; Park IC; Rhee CH
Apoptosis; 2007 Jan; 12(1):195-209. PubMed ID: 17136320
[TBL] [Abstract][Full Text] [Related]
19. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
[TBL] [Abstract][Full Text] [Related]
20. Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
Lei L; Zhang Y; Jian Q; Lei L; Lv N; Williamson RA; Chen P; Zhang D; Hu J
Exp Physiol; 2021 Feb; 106(2):438-449. PubMed ID: 33336554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
